Abstract Given q as the global frequency of the alleles causing a disease, any allele with a frequency higher than q minus the cumulative frequency of the previously known disease-causing mutations (threshold) cannot be the cause of that disease. This principle was applied to the analysis of cystic fibrosis transmembrane conductance regulator (CFTR) mutations in order to decide whether they are the cause of cystic fibrosis. A total of 191 DNA samples from random individuals from Italy, France, and Spain were investigated by DGGE (denaturing gradient gel electrophoresis) analysis of all the coding and proximal non-coding regions of the gene. The mutations detected by DGGE were identified by sequencing. The sample size was sufficient to select essentially all mutations with a frequency of at least 0.01. A total of 46 mutations was detected, 20 of which were missense mutations. Four
Introduction
In an age when molecular genetic analysis has identified several hundreds of different mutations for many diseasecausing genes, a common problem is to decide which mutations are disease-causing and which are not. The role of a not-obviously-pathogenic (e.g., frameshift or stop codon) gene mutation in causing a disease is usually assessed through its frequency in clinically characterized patients and confirmed through evolutionary conservation comparisons or functional studies in vitro or in experimental animal models. However, given the enormous number of known gene mutations for most genetic diseases, this is not feasible for all mutations. Therefore, alternative approaches to establish the possible involvement of a gene in disease etiopathogenesis would be useful.
We propose here a conceptually straightforward method to identify non-pathogenic mutations. We have applied this method to the analysis of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in which more than 800 different mutations have previously been described (Cystic Fibrosis Genetic Analysis Consortium, CFGAC website). One must remember, however, that CFTR gene mutations could be related to different diseases. Indeed, they are not only related to the classical form of cystic fibrosis (CF) but also to atypical forms of the disease (Estivill 1996) , congenital bilateral absence of the vas deferens (Chillon et al. 1995) , disseminated bronchiectasis (Pignatti et al. 1995; Girodon et al. 1997; Bombieri et al. 1998) , chronic pancreatitis (Cohn et al. 1998; Sharer et al. 1998) , and others. Since the only wellcharacterized spectrum of CFTR gene mutations in many different populations is related to CF, this will be the only disease considered here. This project concerns the classi-fication of non-CF-causing mutations with a thorough analysis of all the coding and flanking non-coding sequences of the CFTR gene in random individuals from various European countries.
Materials and methods

Statistical analysis
The rationale of the present approach for identifying pathogenic genes is based on the consideration that any mutation more frequent than the difference between the global frequency of the disease-causing mutations and the cumulative frequency of the previously known disease-causing mutations cannot be the cause of the disease ("common", hence non-pathogenic, mutations). This difference is the "threshold" above which a mutation is defined as a common (C) mutation. The statistical efficiency of the approach corresponds to the proportion of C mutations that are expected to be discovered and recognized as common. For each C mutation, this efficiency depends on two distinct probabilities: (1) the probability of being included in the sample under study, and (2) the probability that it is recognized as being common.
The probability that a mutation is included in the sample was calculated as follows: P=(1-P 0 ), where P 0 is the probability of not being included. P 0 was calculated according to Poisson's distribution: P 0 =(µ 0 /0!) e -µ , where µ is the expected absolute frequency of the mutation in the sample (Fig. 1) . As far as point (2) above is concerned, a mutation can be classified with certainty as being common if its frequency has been established to be higher than the threshold. This condition is fulfilled if f obs -2.5SE is greater than the threshold. In the case of CF in southern Europe, the threshold is 0.004, since the global frequency of CF mutations in Europe is about 0.02, that of ∆F508 is about 0.01 in Italy (Bonizzato et al. 1994; Rendine et al. 1997) , in Southern France (Claustres et al. 1993) , and in Spain (Estivill et al. 1997) , and the combined frequency of the other most common CF mutations is about 0.006. Therefore the probability that a C mutation is classified as being common (hence non-CF-causing) was calculated as follows: f obs must be at least equal to 0.004+2.5SE; this value f minimal is 0.025, 0.015, 0.012, and 0.009 when N is 380, 1000, 1500, and 3000, respectively. This is the same as saying, for example, that, in a sample of 3000 genes, only the mutations with an observed frequency of at least 0.009 can be classified with certainty as C mutations, i.e., 0.009-2.5 (0.009×0.991)/3000. For each mutation with a true frequency f true higher than 0.004, its probability of exhibiting a frequency higher than f minimal was obtained as follows: the algebric difference D = f minimal -f true is standardized by dividing it by the SE of f true ; the one-tail probability of standardized D is derived from the normal distribution table. When D is negative, the value to be plotted is 1 -the value found in the one-tail probability, instead of the value itself.
Samples
Four population samples, with a total of 191 individuals, were studied. One sample consisted of 50 individuals, each of whom had all four grandparents born in Veneto (North-East Italy). Another sample consisted of 50 individuals, each with four grandparents born in Latium or Umbria or Abruzzi (Central Italy). The third sample consisted of 50 individuals whose parents and grandparents lived in Southern France. The fourth sample consisted of 41 individuals who were spouses of CF carriers and born in Spain. In order to avoid strictly local effects, each subsample was made up of individuals living in a large town. Blood specimens were collected after informed consent.
Mutation analysis
The whole coding (with the exception of the first 10 nucleotides of the 13th exon) and partial proximal non-coding sequences were analysed (see Table 1 ). Genomic DNA was prepared from periph- Fig. 1 Probability P D (detection) that a mutation happens to be included in the sample, as a function of its frequency. N is the number of genes examined. One hundred and 380 indicate the approximate size of each of the four subsamples and that of the total sample of the present work, respectively. The arrow indicates the detectability limit, i.e., the value above which all mutations are expected to be detected with the N=380 sample size used in this study eral blood samples by standard methods. Polymerase chain reaction (PCR) DNA amplification and denaturating gradient gel electrophoresis (DGGE) were performed as described (Fanen et al. 1992; Costes et al. 1993) or after local modifications (M. Claustres et al., unpublished) . Every mutant discovered by this method was sequenced either manually or with the ABI Prism 377 or 310 sequence analyser. The IVS8-6 polymorphism (a stretch of 5, 7, or 9 T) was studied as described (Chillon et al. 1995) . The IVS8 (TG) m polymorphism (a stretch of 10, 11, or 12 TG) was also studied as described (Strasberg et al. 1997) . For the Spanish sample only, 12 CFTR gene exons (1, 2, 4, 6b, 7, 10, 13b, 16, 17a, 19, 22, 24) were analyzed by single-strand conformation analysis (SSCA) as previously described (Chillon et al. 1994 ). The 4521 G/A mutation was studied in all subjects by a restriction modification assay (Gasparini et al. 1992) , because DGGE does not distinguish between the two types of homozygotes. According to Macek et al. (1997) , the sensitivity of the DGGE method with respect to detecting mutations in the CFTR gene is about 100%. In our hands, this method exhibited a sensitivity of 98.6%, as we have easily detected 73 out of 74 mutations not originally discovered by DGGE.
Results
Statistical approach
The purpose of the present approach is to identify as many C mutations as possible. The probability of each of these mutations being classified as C is the result of: (1) the probability of being detected, (2) the probability of conclusively demonstrating that its frequency is higher than 0.004. From a statistical point of view, both points (1) and (2) are a function of the frequency q of the mutation and of the sample size of random genes examined. Figure 1 shows the probability of detecting a mutation as a function of frequency and sample size. With a sample of 380 genes (as that of the present study), roughly 15% of the mutations with a frequency around 0.005 are expected not to be included in the sample. Figure 2 shows the probability of a mutation being classified as a C mutation as a function of the frequency for various sample sizes. With a sample of 3000 genes, 50% of the mutations with a frequency around 0.009 are expected not to be demonstrated as C mutations. C mutations can be subdivided into three classes differing from one another with respect to (1) the rate of statistical detectability, i.e., the probability that the mutation happens to be included in the sample, and (2) statistical demonstrability, i.e., the probability of showing that the mutation is a C mutation by finding that its q obs -2.5SE is greater than 0.004. The classification of C mutations is shown in Table 2 . The most relevant feature is the dramatic difference between the sample size required to ensure a satisfactory rate of statistical detectability and that required to attain a satisfactory rate of statistical demonstrability, which is one order of magnitude larger. The obvious implication is that a full detectability of all the C mutations can be reasonably achieved, but not a full demonstrability. In particular, mutations with a frequency 0.004<q<0.01, i.e., the "impossible" to demonstrate (ID-C) mutations, may not be identified with certainty as C mutations.
On the basis of the above considerations, this is a twostep project. The first phase aims are (1) to detect and identify every "easy" to demonstrate (ED-C) mutation as C; (2) to detect every "difficult" to demonstrate (DD-C) mutation present in the populations under study. The second phase aim is to identify which mutations, if any, among those detected in the first phase and still not classified with respect to pathogenicity, can be recognized with certainty as being C mutations. The first phase demands the full analysis of the CFTR gene (all of its 27 exons and flanking intronic sequences) in a relatively small sample (a few hundred); the second phase requires a specific search limited to the mutations detected in the first phase and of still uncertain clinical meaning, but on a larger sample (a few thousand).
Mutations found in the sample
The complete list of the mutations found in this work and their frequency is given in Table 3 ; 42 sites with two alleles and two sites with three alleles have been detected corresponding to a total 44 sites and 90 alleles. These findings include four novel mutations described here for the first time: 1341+28 C/T, 2082 C/T, L1096R, and I1131V.
For each mutation, the frequencies observed in the four subsamples were not significantly different from each other after correcting for multiple comparisons. They were therefore pooled, and a combined frequency was obtained. Since both the statistical efficiencies (for mutations with a q>0.01) and experimental efficiencies were substantially 100%, one can state that all mutations present with a frequency of at least 0.01 in the area under study have been detected and are included in the list shown in Table 3 . The 46 different mutations listed in Table 3 affect sequences of the following types: 31 in the coding sequence (20 missense, 10 samesense, and one trinucleotide deletion: ∆F508), 12 in the intronic sequences, and one in the 5'UTR. Out of the 20 missense mutations, three (G85E, ∆F508, and N1303K) are certainly CF-causing, and several (R31C, K68E, R75Q, I148T, V562L, G576A-R668C, L997F, F1052V, S1235R) have been described in congenital bilateral absence of the vas deferens, in disseminated bronchiectasis, in pancreatitis, or in atypical CF cases mutations as reported in the CFGAC website (). Many (13 out of 20) of the missense mutations change highly conserved (5/5 species analyzed) amino acid residues (R75Q, G85E, I148T, I506V, R668C, G622D, L997F, I1027T, F1052V, L1096R, I1131V, R1162L, N1303K); others affect amino acid residues conserved in 4/5 species (K68 E, R170H, M470V, V562L, S1235R), or in 3/5 species (R31C and G576A; Tucker et al. 1992 ). This distribution is compatible with that observed by comparing these species for the whole coding sequence.
The sum of the absolute frequencies of the 46 mutations was 513 on a total sample of 382 genes (165/100, 113/100, 137/100, and 98/82 in North-East Italy, Central a That an observed mutation is a C mutation b ID-C: "impossible" to demonstrate, in the sense that a sample size of 3000 genes may be insufficient to demonstrate with certainty that one such mutation is indeed a C mutation (by showing that its observed frequency q obs fulfils the condition q obs -2.5SE>0.004) c DD-C: "difficult" to demonstrate, in the sense that the sample size required to show that q obs -2.5SE>0.004 is in the order of 3000 genes d ED-C: "easy" to demonstrate, because a relatively small sample size (380 genes) is expected to be sufficient to show with certainty that such mutations are C mutations Italy, Southern France, and Spain samples, respectively, with an overall highly significant excess in North-East Italy as compared with the other three samples). Therefore, in many cases, two or more mutations are localized in the same gene. In addition to very common mutations, which are often associated with other mutations in the same gene, two sporadic mutations were found together in the same individual (G576A and R668C once; 3041-71 G/C and 4002 A/G twice) in three cases. On the basis of personal observations and of published data (Bombieri et al. 1998) , we believe that these mutations are located in the same genes. In three further cases where more than one sporadic mutation was observed in the same individual (1341+28 C/T and F1052V and S1235R; ∆F508 and I1027T; 1716G/A and N1303K), data from the literature were not available, and segregation analysis was not possible; thus, their phase could not be established.
Discussion
Medical genetics
Thirteen of the 46 variant alleles detected in the present study show a frequency high enough to allow the conclusion that their frequency in the population is certainly higher than 0.004; therefore, they have been classified as C mutations (Table 4) . These are ED-C mutations according to the nomenclature adopted in Table 2 , because their observed frequency (≥0.03) is much higher than the threshold of 0.004. The remaining 30 (after having excluded the certainly CF-causing mutations G85E, ∆F508 and N1303K) have been found a few times only: once (20 mutations), twice (five mutations), three times (three mutations), four times (one mutation), and eight times (one mutation). Two reasons for these mutations having been encountered in the present survey are possible.
(1) The mutation may be one of a very large set of extremely rare mutations, namely one of a set of mutations each having a very low probability of being included by pure chance in a random sample of 400 genes (for example, such a probability would be 4×10 -3 for a mutation with a frequency of 10 -5 ). Obviously, such rare mutations are not to be expected to be found again in future surveys. If n is the number of such mutations, one expects to find, in an additional survey of 400 random genes, once again about n such extremely rare mutations, which should however be different from the present ones. (2) The mutation may be relatively common in the population in which it was found, but rarer in the other populations of the present survey. In a much enlarged sample, a mutation of this kind should be found again in several specimens of the population in which it was originally found and not in the remaining populations. Indeed, in some cases, one may reach the conclusion that a mutation is a C mutation even though its overall observed frequency does not fulfil the condition q obs -2.5SE is greater than 0.004: in order to be classified as a C mutation, it is sufficient that, even in one subsample, its q obs -2.5SE value is higher than 0.004. This is the case for two mutations detectable only with a method used for the Spanish sample (Table 4 ). The distribution in the four samples of mutations observed a few times is given in Table 5 . Even though, considering a multiple comparison correction, no significant sample heterogeneity was found, it appears likely that one or more of the observed inter-ethnic differences is the expression of an actual relatively high frequency of a mutation in the area in which it was found.
Population genetics
The relatively high frequency of the 13 alleles of Table 4 makes them possible candidates as anthropogenetic markers, namely markers of potential usefulness for characterizing populations. Surprisingly enough, this aspect of the CFTR gene seems to have been overlooked. This is probably because of the overwhelming clinical interest in the CFTR gene. The common variants of the CFTR gene appear to be evenly distributed in Southern Europe since, considering a multiple comparison correction, no obvious differences in their frequencies have been found between the four random samples of the present survey. The next step will consist of estimating the frequency of these alleles for other European and non-European populations in order to identify which, if any, will be a potentially useful anthropogenetic marker.
Structural gene evolution
The present survey is, to the best of our knowledge, the first deliberate and systematic random search for polymorphic mutations in a structural gene with a method close to 100% efficiency. This approach, therefore, fulfils the conditions required to obtain a reliable estimate of the common variability of the structural gene under study, with a characterization of the functional distribution, e.g., introns vs exons, missense-single-nucleotide-substitution (SNS) vs samesense-SNS mutations, etc., and the spatial distribution of the mutations. The limit of this survey is that it concerns a single, although large, gene; the results cannot therefore be extrapolated to all structural genes.
Four types of variable sites, such as SNS (31 exonic and 8 intronic), deletions (one), insertions (one), and simple tandem repeats (three), were found in the present study.
The density of polymorphic sites, which is essentially the proportion of sites susceptible to evolving among the total number of sites (bp) of that gene, can be estimated by counting the number n of polymorphic sites existing in 177 
a Given its frequency and distribution, this mutant will probably turn out to be a C mutant the stretch under study of N bp and dividing n by N. Usually, the number of sites identified as polymorphic sites is merely a minimum estimate of the total number n of polymorphic sites of the N stretch, because the number of polymorphic sites of the stretch that escaped detection remains unknown. The present investigation is an exception to this rule, since the sample size and the technique adopted should have enabled us to detect every existing mutation with a polymorphic frequency at least once (with the practically negligible exception of those with a frequency q ranging between 0.005 and 0.01). Therefore, the highest possible number of polymorphic sites in the DNA under study simply corresponds to the number of mutations observed (assuming that all the observed mutations are polymorphic). Thus, the present data identify both the minimum (n min =13, i.e., the number of sites already classified as polymorphic; Table 4 ) and the maximum number of polymorphisms (n max : if all the 46 variations of Table 3 are polymorphic). It is therefore possible to define the range of uncertainty of the density of polymorphic sites n/N precisely. The true n will become known by searching for the 33 remaining mutations not yet classified as C mutations in a random sample of 2500 more alleles (second phase of the research project). The overall density is a coarse parameter to describe n/N. Therefore, this density of polymorphic sites will be considered separately for each SNS type. The maximum number of missense, samesense, and intronic SNSs possible in the studied sequence is 2862, 9815, and 6552, respectively. The number of SNSs found was 6, 6, and 3, respectively. The ratio n obs /n possible of samesense mutations was three times larger than that of missense mutations.
These findings, although preliminary, suggest that the rate of common samesense variation is not much higher than that of the missense variation as implied by the theory that polymorphisms are, as a rule, neutral polymorphisms.
